PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.
Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.
PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.
$PTC Therapeutics(PTCT.US)$🚀🚀🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥🔥🔥 Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for $1.0 billion upfront -- PTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 million -- Transaction expected to enhance long-term Adjusted Cash Receipts growth (non-GAAP) -- R...
PTC Therapeutics, Inc. today announced positive results from a long-term real-world study of Translarna (Ataluren), a small molecule therapy. Data from 241 patients showed that Translarna delayed bedside mobility by more than 5 years and reduced lung function by an average of 1.8 years in boys with nonsense mutant Duchenne muscular dystrophy compared with standard therapy alone.$PTC Therapeutics(PTCT.US)$
PTC Therapeutics股票討論區
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
暫無評論